2529. Population pharmacokinetic models for cefepime and enmetazobactam derived from pooled Phase 1 to Phase 3 clinical studies

BACKGROUND: The investigational β-lactam/β-lactamase inhibitor combination of cefepime (FEP)/enmetazobactam (ENM) met criteria for non-inferiority and superiority compared to piperacillin/tazobactam in a phase 3 clinical trial of adult patients with complicated urinary tract infections (cUTI)/acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollmer, Jannik, Belley, Adam, Velicitat, Patrick, Machacek, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677492/
http://dx.doi.org/10.1093/ofid/ofad500.2147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677492/
http://dx.doi.org/10.1093/ofid/ofad500.2147

Ejemplares similares